Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 CNS-targeting pharmacological interventions for the metabolic syndrome.

Literature DB >> 31380808

CNS-targeting pharmacological interventions for the metabolic syndrome.

Kerstin Stemmer^1,2, Timo D Müller^1,2, Richard D DiMarchi³, Paul T Pfluger^1,2, Matthias H Tschöp^1,2,4.

Abstract

The metabolic syndrome (MetS) encompasses medical conditions such as obesity, hyperglycemia, high blood pressure, and dyslipidemia that are major drivers for the ever-increasing prevalence of type 2 diabetes, cardiovascular diseases, and certain types of cancer. At the core of clinical strategies against the MetS is weight loss, induced by bariatric surgery, lifestyle changes based on calorie reduction and exercise, or pharmacology. This Review summarizes the past, current, and future efforts of targeting the MetS by pharmacological agents. Major emphasis is given to drugs that target the CNS as a key denominator for obesity and its comorbid sequelae.

Entities: Disease

Year: 2019 PMID： 31380808 PMCID： PMC6763237 DOI： 10.1172/JCI129195

Source DB: PubMed Journal: J Clin Invest ISSN： 0021-9738 Impact factor: 14.808

198 in total

1. AgRP neurons regulate development of dopamine neuronal plasticity and nonfood-associated behaviors.

Authors: Marcelo O Dietrich; Jeremy Bober; Jozélia G Ferreira; Luis A Tellez; Yann S Mineur; Diogo O Souza; Xiao-Bing Gao; Marina R Picciotto; Ivan Araújo; Zhong-Wu Liu; Tamas L Horvath
Journal: Nat Neurosci Date: 2012-06-24 Impact factor: 24.884

2. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Authors: Frank L Greenway; Ken Fujioka; Raymond A Plodkowski; Sunder Mudaliar; Maria Guttadauria; Janelle Erickson; Dennis D Kim; Eduardo Dunayevich
Journal: Lancet Date: 2010-07-29 Impact factor: 79.321

3. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.

Authors: W Philip T James; Ian D Caterson; Walmir Coutinho; Nick Finer; Luc F Van Gaal; Aldo P Maggioni; Christian Torp-Pedersen; Arya M Sharma; Gillian M Shepherd; Richard A Rode; Cheryl L Renz
Journal: N Engl J Med Date: 2010-09-02 Impact factor: 91.245

4. Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats.

Authors: F Picard; Y Deshaies; J Lalonde; P Samson; D Richard
Journal: Obes Res Date: 2000-12

5. MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency.

Authors: Karine Clément; Heike Biebermann; I Sadaf Farooqi; Lex Van der Ploeg; Barbara Wolters; Christine Poitou; Lia Puder; Fred Fiedorek; Keith Gottesdiener; Gunnar Kleinau; Nicolas Heyder; Patrick Scheerer; Ulrike Blume-Peytavi; Irina Jahnke; Shubh Sharma; Jacek Mokrosinski; Susanna Wiegand; Anne Müller; Katja Weiß; Knut Mai; Joachim Spranger; Annette Grüters; Oliver Blankenstein; Heiko Krude; Peter Kühnen
Journal: Nat Med Date: 2018-05-07 Impact factor: 53.440

6. Leptin replacement alters brain response to food cues in genetically leptin-deficient adults.

Authors: Kate Baicy; Edythe D London; John Monterosso; Ma-Li Wong; Tuncay Delibasi; Anil Sharma; Julio Licinio
Journal: Proc Natl Acad Sci U S A Date: 2007-11-06 Impact factor: 11.205

7. Vagal mediation of the cholecystokinin satiety effect in rats.

Authors: D N Lorenz; S A Goldman
Journal: Physiol Behav Date: 1982-10

8. Supraphysiological doses of intravenous PYY3-36 cause nausea, but no additional reduction in food intake.

Authors: Carel W le Roux; Cynthia M Borg; Kevin G Murphy; Royce P Vincent; Mohammad A Ghatei; Stephen R Bloom
Journal: Ann Clin Biochem Date: 2008-01 Impact factor: 2.057

9. GLP-1 influences food and drug reward.

Authors: Matthew R Hayes; Heath D Schmidt
Journal: Curr Opin Behav Sci Date: 2016-06

10. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.

Authors: Kathleen M Dungan; Santiago Tofé Povedano; Thomas Forst; José G González González; Charles Atisso; Whitney Sealls; Jessie L Fahrbach
Journal: Lancet Date: 2014-07-10 Impact factor: 79.321

7 in total

Review 1. Signaling pathways in obesity: mechanisms and therapeutic interventions.

Authors: Xue Wen; Bohan Zhang; Beiyi Wu; Haitao Xiao; Zehua Li; Ruoyu Li; Xuewen Xu; Tao Li
Journal: Signal Transduct Target Ther Date: 2022-08-28

2. Brain O-GlcNAcylation: From Molecular Mechanisms to Clinical Phenotype.

Authors: Batuhan Uygar; Olof Lagerlöf
Journal: Adv Neurobiol Date: 2023

Review 3. Potential Role of Dexamphetamine in the Treatment of Non-alcoholic Fatty Liver Disease: Hopes and Pitfalls.

Authors: C S Gautam; Jatin Sharma; Mandeep Singla; Ilmjot Kaur Tiwana; Harmanjit Singh
Journal: touchREV Endocrinol Date: 2021-04-28

4. Diabetes type 2 risk gene Dusp8 is associated with altered sucrose reward behavior in mice and humans.

Authors: Peter Baumann; Sonja C Schriever; Stephanie Kullmann; Annemarie Zimprich; Andreas Peter; Valerie Gailus-Durner; Helmut Fuchs; Martin Hrabe de Angelis; Wolfgang Wurst; Matthias H Tschöp; Martin Heni; Sabine M Hölter; Paul T Pfluger
Journal: Brain Behav Date: 2020-11-01 Impact factor: 2.708